Radiculopathy
Drug research and approvals for radiculopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 75 studies of radiculopathy are recruiting on ClinicalTrials.gov, and Health Canada has authorized 1 drug trials for it since 2013.
- Recruiting worldwide: 75
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Correlation Between Forward Head Posture and Executive Functions in Cervical RadiculopathyNCT07906847 · Not reported · Cairo University · starts Nov 4, 2026
- Ultrasound-Guided Electrical Dry Needling for Chronic Cervical RadiculopathyNCT07907562 · Not applicable · Liberty University · starts Nov 2, 2026
- Comparative Effect Between Mulligan Leg Raise and Spinal Mobilization With Limb Movement in Lumbar RadiculopathyNCT07887685 · Not applicable · Foundation University Islamabad · starts Sep 23, 2026
- Effect of Transfer of Energy Capacitive and Resistive on Chronic Discogenic SciaticaNCT07841405 · Not applicable · Cairo University · starts Sep 21, 2026
- Gelified Radiopaque Ethanol (Absolute Gel) in Cervical Disc Herniation: an Observational Study in Routine Clinical…NCT07832929 · Not reported · Aurel Mengri · starts Mar 10, 2025
- Effectiveness and Safety of Pharmacopuncture Therapy for Chronic Lumbar Radiculopathy: A Multicenter, Pragmatic,…NCT07832318 · Not applicable · Jaseng Medical Foundation · starts Aug 22, 2025
- Cervical Spinal Cord Signal Abnormalities in Patients With Cervical Radicular PainNCT07823426 · Not reported · Ankara City Hospital Bilkent · starts Oct 1, 2026
- Efficacy Of Gross Myofascial Release With Neural Mobilization Versus Neural Mobilization Alone On Pain, Functional…NCT07808476 · Not applicable · Ibadat International University, Islamabad · starts Jul 10, 2026
- Femoral Stretch Test in L2-L4 Lumbar RadiculopathyNCT07799142 · Not reported · Marmara University · starts Sep 7, 2026
Phase 3 6
- BupivacaineSodium channel protein type IV alpha subunit blocker
- DiclofenacCyclooxygenase inhibitor
- Triamcinolone acetonideGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- TizanidineAdrenergic receptor alpha-2 agonist
- PregabalinVoltage-gated calcium channel modulator
Phase 2 5
- DexamethasoneGlucocorticoid receptor agonist
- VixotrigineSodium channel protein type IX alpha subunit blocker
- EtanerceptTNF-alpha inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Z160Voltage-gated N-type calcium channel alpha-1B subunit blocker
Phase 1 or earlier 4
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- GadoliniumDiagnostic (when bound to a chelating agent)
- Artemin
- LAT-8881
How its trials ended
383 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 60 whose ending is known, 22% met their primary endpoint, 10% missed it and 68% stopped early.
- Completed, result not reported16944%
- Ongoing9625%
- Status unknown5815%
- Stopped: other or unclear195%
- Met its primary endpoint133%
- Stopped: enrollment or feasibility123%
- Missed its primary endpoint62%
- Stopped: sponsor or business decision41%
- Stopped: funding31%
- Stopped: lack of efficacy21%
- Stopped: safety1<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Apr 7, 2017 | Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of newgam in patients with chronic…Newgam (PANZYGA) | Octapharma Pharmazeutika Produktionsges M B H | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA